Wells Fargo Downgrades Zentalis Pharma to Equal-Weight, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has downgraded Zentalis Pharma (NASDAQ:ZNTL) from Overweight to Equal-Weight and significantly lowered the price target from $29 to $9.
June 18, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Derek Archila downgraded Zentalis Pharma from Overweight to Equal-Weight and reduced the price target from $29 to $9.
The downgrade from Overweight to Equal-Weight and the significant reduction in the price target from $29 to $9 by a major financial institution like Wells Fargo is likely to negatively impact investor sentiment and the stock price of Zentalis Pharma in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100